Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenofovir disoproxil orotate - Dong-A ST

Drug Profile

Tenofovir disoproxil orotate - Dong-A ST

Alternative Names: DA 2802

Latest Information Update: 21 Apr 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A ST
  • Class Amines; Antiretrovirals; Antivirals; Esters; Phosphonic acids; Purines; Pyrimidines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis B

Most Recent Events

  • 21 Apr 2021 Phase-III development is ongoing for Hepatitis B in South Korea (PO) (NCT02967939)
  • 05 Oct 2020 No development reported - Phase-III for Hepatitis B in South Korea (PO) (Dong-A ST website, October 2020)
  • 15 Jul 2019 Dong-A ST completes a phase-III clinical trials in Hepatitis B in South Korea (PO) (NCT02967939)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top